Analysts are intrested in these 5 stocks: ( (ZM) ), ( (QTTB) ), ( (AA) ), ( (GNRC) ) and ( (EOSE) ). Here is a breakdown of their recent ratings and the rationale behind them.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Zoom Video Communications is back in analysts’ good graces after a rough start. Jackson Ader at KeyBanc admits his bearish thesis was wrong, upgrading Zoom from Underweight to a more neutral Sector Weight as both enterprise and online businesses beat expectations and bookings accelerated.
He highlights better margins, resilient demand for Zoom Phone and Contact Center, and a powerful kicker from the company’s early investment in AI firm Anthropic, now worth well over the original stake. While some of the share price strength reflects improved sentiment in cloud communications, the analyst sees a healthier growth runway than a year ago.
Q32 Bio is drawing fresh attention as a speculative biotech with a focused bet on alopecia areata. Mizuho’s Joseph Catanzaro starts coverage with a Buy rating and a $14 target, arguing that lead drug bempikibart could offer disease‑modifying hair regrowth without the safety baggage of current JAK inhibitors.
The firm sees mid‑2026 Phase II data as a key catalyst that could “de‑risk” the story and support hundreds of millions in long‑term global sales if results stay on track. With trial design tweaks aimed at boosting efficacy and a clear proof‑of‑concept already in hand, Q32 Bio is being positioned as a high‑risk, high‑reward name in dermatology.
Alcoa is suddenly back on the offensive as aluminium markets tighten. UBS analyst Daniel Major upgrades the stock to Buy with an $80 target, arguing that prolonged smelter outages tied to Middle East conflict are set to outweigh soft demand and keep aluminium prices and premiums higher for longer.
He thinks the market underestimates Alcoa’s earnings resilience and cash‑flow power at today’s price deck, seeing room for net debt to drop well below the company’s own targets by 2026. That could unlock share buybacks, potential asset sales like the idle Massena East smelter, and a valuation re‑rating.
Generac Holdings is getting a second look as a stealth data‑center winner. Jefferies’ Tanner James upgrades GNRC to Buy with a $302 price target, pointing to “multiple shots on goal” as the company negotiates large backup‑generator deals with several hyperscale cloud operators.
He notes that Generac’s Baudouin engines are increasingly visible in big server‑farm plans and believes at least one major hyperscaler contract is close after a $600 million preliminary notice. With shares trading at a discount to industrial peers and residential trends looking manageable, the analyst sees an appealing upside skew into 2028.
Eos Energy Enterprises rounds out the list as a niche play on long‑duration energy storage. Needham initiates coverage at Buy with an $11 target, describing EOSE as a domestic “pure‑play” on utility‑scale zinc‑battery systems just as the company ramps its second production line.
The call stresses that the story has moved from lab credibility to factory execution, with investors now watching whether Eos can turn a $24 billion project pipeline into firm contracts. If it delivers on manufacturing and margins, the stock could benefit from rising grid needs, AI‑driven power demand, and U.S. content rules favoring homegrown suppliers.